omniture
iNtRON Biotechnology, Inc.

Latest News

iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology

▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvem...

2024-02-15 11:37 1594

iNtRON, Executes Evaluation License and Option Agreement for SAL200

* iNtRON Grants Basilea exclusive right for preclinical evaluation with an undisclosed payment ...

2023-10-31 12:20 1326

iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome

* It was confirmed the presence of Prophage and Jamphage in the Alkalihalobacillus clausii * Pr...

2023-05-30 10:15 1833

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

* Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoi...

2023-04-04 10:33 2184

iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax

* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in...

2023-01-26 10:34 1919

iNtRON is finalizing the SAL200 Tech Transfer

* Including the contract transfers of the external studies planned for the successful out-licensi...

2023-01-12 09:34 1974

iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis

* The transposon technology development following the customized CRISPR/Cas system for bacterioph...

2022-10-18 11:56 1482

iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform

* CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes * Customized ge...

2022-08-10 09:00 1580

iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates

* Shows potent and rapid antibacterial activity against clinical isolates in Europe and Korea bot...

2022-07-12 10:06 1600

iNtRON to Seek a New Clinical Partner for SAL200 Endolysin

* TONABACASE, the first registered INN by WHO for Endolysin * First-in-Class Endolysin-based Dru...

2022-06-28 21:00 1707

iNtRON Completes GLP-TOX Studies of BAL200

* A novel drug candidate for anthrax received orphan drug designation (ODD) by the US FDA. BOSTON...

2022-06-07 09:00 2005

iNtRON Biotechnology, Inc., Launches New Website

It aims to promote strategic collaborations in global while also highlights its many innovative adv...

2022-05-09 21:00 1838